A phase I study of hepatic arterial infusion using difluoromethylornithine

Allan Lipton, Harold A. Harvey, Jerry Glenn, William A. Weidner, Melvin Strauss, Sharon E. Miller, Jerlynn B. Taylor, Deborah White‐Hershey, John L.R. Barlow

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Ten patients with metastatic disease to the liver were treated with difluoromethylornithine (DFMO) administered by continuous hepatic arterial infusion. Two of nine evaluable patients had an objective partial response. Stable disease was recorded in three patients. Ototoxicity was encountered in all patients who received a daily dose of DFMO equal to or greater than 1.0 g/m2.

Original languageEnglish (US)
Pages (from-to)433-437
Number of pages5
JournalCancer
Volume63
Issue number3
DOIs
StatePublished - Feb 1 1989

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase I study of hepatic arterial infusion using difluoromethylornithine'. Together they form a unique fingerprint.

  • Cite this

    Lipton, A., Harvey, H. A., Glenn, J., Weidner, W. A., Strauss, M., Miller, S. E., Taylor, J. B., White‐Hershey, D., & Barlow, J. L. R. (1989). A phase I study of hepatic arterial infusion using difluoromethylornithine. Cancer, 63(3), 433-437. https://doi.org/10.1002/1097-0142(19890201)63:3<433::AID-CNCR2820630306>3.0.CO;2-5